Use of EGFL6 in preparing serum marker for detecting benign meningiomas

Abstract

The invention belongs to the bio-medical field, and relates to a use of EGFL6 as a serum marker for detecting benign meningiomas and a method for detecting and analyzing different expression levels of EGFL6. According to the invention, a differential gene expression profile between different types of meningiomas and brain arachnoid tissue is established by means of a gene chip, the level of EGFL6mRNA in each of the brain arachnoid tissue, the meningiomas and other tumors is measured by real-time quantitative PCR technology, and the content of EGFL6 in each of serum samples of healthy people and various tumor patients is detected by a double sandwich ELISA (Enzyme Linked Immunosorbent Assay) method. Results verify that the EGFL6 can be taken as a new serum marker for benign meningiomas and also can be used for further preparing a diagnosing and classifying kit for detecting benign and malignant meningiomas, and meaningful reference information for diagnosis and classification of preoperative or early benign and malignant meningiomas is provided.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a serum marker for detection, in particular to the use of EGFL6 in preparing serum markers for detecting benign meningiomas and a method for detecting EGFL6. Background technique [0002] Meningiomas are known to be mesenchymal tumors originating from arachnoid cells in the meninges that cover the surface of the brain and spinal cord, accounting for about 30% of all primary intracranial tumors. According to the WHO grading system, meningiomas are divided into benign WHO grade I (about 80% of all meningiomas), atypical WHO grade II (5%-20%) and anaplastic WHO grade III (1%-2%). According to the histopathological characteristics of tumor cells, grade I meningiomas are divided into different subtypes, such as epithelial, fibrous, transitional, pumice, hemangioma, and secretory. [0003] At present, there is still a lack of sensitive and specific serum markers for the diagnosis of meningioma...

AI Technical Summary

Problems solved by technology

Yeung et al. reported that EGFL6 was highly expressed in embryonic tissues and adult meningioma tissues, and detected its transcription levels in normal tissues, glioma tissues and malignant lymphoma tissues, but for other tumor tissues The level of EGFL6 in the

In addition, although Oberauer et al. have detected EGFL6 in the culture medium by direct ELISA, there is no report on the quantitative analysis of EGFL6 in serum.

Images